Fast Five Quiz: Chronic Lymphocytic Leukemia (CLL) Treatment

Karl J. D'Silva, MD; Christina Poh, MD


November 02, 2021

Figure 1. Stem cell therapy

The presence of del(17p) or TP53 mutations is associated with low responses with standard chemoimmunotherapy regimens and favorable responses with targeted therapy such as small-molecule inhibitors. Although del(13q) is associated with favorable outcomes and del(11q) and complex karyotype are associated with inferior outcomes, they do not influence the initial treatment approach.

Learn more about CLL prognosis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.